Alaunos Therapeutics, Inc. Amortization of Debt Issuance Costs
Alaunos Therapeutics, Inc. (TCRT) reported Amortization of Debt Issuance Costs of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2025-03-31
- Alaunos Therapeutics, Inc. amortization of debt issuance costs for the quarter ending 2024-12-31 was $0.00.
- Alaunos Therapeutics, Inc. amortization of debt issuance costs for the quarter ending 2024-09-30 was $0.00.
- Alaunos Therapeutics, Inc. amortization of debt issuance costs for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- Alaunos Therapeutics, Inc. amortization of debt issuance costs for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- Alaunos Therapeutics, Inc. amortization of debt issuance costs for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Alaunos Therapeutics, Inc. amortization of debt issuance costs for fiscal 2023 was $1.34M, a 36.49% increase from fiscal 2022.
- Alaunos Therapeutics, Inc. amortization of debt issuance costs for fiscal 2022 was $981.00K, a 156.14% increase from fiscal 2021.
- Alaunos Therapeutics, Inc. amortization of debt issuance costs for fiscal 2021 was $383.00K.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $0.00 derived: sum of 2 quarters · filed 2025-03-31 | $0.00 derived: sum of 3 quarters · filed 2025-03-31 | $0.00 10-K · filed 2025-03-31 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $0.00 derived: sum of 2 quarters · filed 2024-11-14 | $0.00 10-Q · filed 2024-11-14 | $0.00 derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $0.00 10-Q · filed 2024-08-14 | $0.00 derived: sum of 3 quarters · filed 2025-03-31 | $0.00 derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-15 | $0.00 derived: sum of 2 quarters · filed 2025-03-31 | $0.00 derived: sum of 3 quarters · filed 2025-03-31 | $867.00K derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $0.00 derived: sum of 2 quarters · filed 2025-03-31 | $867.00K derived: sum of 3 quarters · filed 2025-03-31 | $1.34M 10-K · filed 2025-03-31 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $867.00K derived: sum of 2 quarters · filed 2024-11-14 | $1.34M 10-Q · filed 2024-11-14 | $1.69M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $867.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $1.34M 10-Q · filed 2024-08-14 | $1.69M derived: sum of 3 quarters · filed 2024-08-14 | $1.92M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $472.00K 10-Q · filed 2024-05-15 | $819.00K derived: sum of 2 quarters · filed 2024-05-15 | $1.05M derived: sum of 3 quarters · filed 2024-05-15 | $1.25M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $347.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $576.00K derived: sum of 2 quarters · filed 2024-04-01 | $783.00K derived: sum of 3 quarters · filed 2024-04-01 | $981.00K 10-K · filed 2024-04-01 |
| 2022-09-30 | $229.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $436.00K derived: sum of 2 quarters · filed 2023-11-14 | $634.00K 10-Q · filed 2023-11-14 | $869.00K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $207.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $405.00K 10-Q · filed 2023-08-14 | $640.00K derived: sum of 3 quarters · filed 2023-08-14 | $788.00K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $198.00K 10-Q · filed 2023-05-10 | $433.00K derived: sum of 2 quarters · filed 2023-05-10 | $581.00K derived: sum of 3 quarters · filed 2023-05-10 | $581.00K derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $235.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $383.00K derived: sum of 2 quarters · filed 2023-03-07 | $383.00K derived: sum of 3 quarters · filed 2023-03-07 | $383.00K 10-K · filed 2023-03-07 |
| 2021-09-30 | $148.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $148.00K derived: sum of 2 quarters · filed 2022-11-14 | $148.00K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $0.00 10-Q · filed 2022-08-15 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | $0.00 10-K · filed 2022-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |